| Name | KRAS G12C inhibitor 18 |
|---|
| Description | KRAS G12C inhibitor 18 is a potent and orally active KRAS G12C inhibitor. Anti-tumor activities[1]. |
|---|---|
| Related Catalog | |
| Target |
KRas G12C |
| In Vitro | KRAS G12C inhibitor 18 (compound 34) inhibits the growth of many KRas G12C mutant tumor cell lines (such as H358, SW1436, MiaPaca-2 cells, etc.)[1]. |
| In Vivo | KRAS G12C inhibitor 18 exhibits a dose dependent inhibiton of pERK and active KRas after a single dose treatment from 12.5 to 100 mg/kg at 8 hours[1]. KRAS G12C inhibitor 18 (30 mg/kg; p.o.; twice daily) exhibits anti-tumor growth activity in lung cancer H358 xenograft mouse model[1]. |
| References |
[1]. Serge Louis Boulet, et al. Kras g12c inhibitors. WO2021118877A1. |
| Molecular Formula | C25H20ClFN4O3S |
|---|---|
| Molecular Weight | 510.97 |